(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of -31.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Kymera Therapeutics's revenue in 2026 is $102,235,000.On average, 27 Wall Street analysts forecast KYMR's revenue for 2026 to be $8,650,683,658, with the lowest KYMR revenue forecast at $8,199,068,968, and the highest KYMR revenue forecast at $9,089,492,639. On average, 26 Wall Street analysts forecast KYMR's revenue for 2027 to be $3,471,627,859, with the lowest KYMR revenue forecast at -$1,087,631,598, and the highest KYMR revenue forecast at $9,349,875,399.
In 2028, KYMR is forecast to generate $3,853,835,603 in revenue, with the lowest revenue forecast at -$2,091,599,227 and the highest revenue forecast at $13,445,995,028.